139 related articles for article (PubMed ID: 12727077)
1. Telithromycin (HMR 3647) achieves high and sustained concentrations in tonsils of patients undergoing tonsillectomy.
Gehanno P; Sultan E; Passot V; Nabet P; Danon J; Romanet P; Attal P
Int J Antimicrob Agents; 2003 May; 21(5):441-5. PubMed ID: 12727077
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis.
Norrby SR; Quinn J; Rangaraju M; Leroy B
Clin Microbiol Infect; 2004 Jul; 10(7):615-23. PubMed ID: 15214873
[TBL] [Abstract][Full Text] [Related]
3. Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).
Muller-Serieys C; Soler P; Cantalloube C; Lemaitre F; Gia HP; Brunner F; Andremont A
Antimicrob Agents Chemother; 2001 Nov; 45(11):3104-8. PubMed ID: 11600363
[TBL] [Abstract][Full Text] [Related]
4. Penetration of telithromycin (HMR 3647), a new ketolide antimicrobial, into inflammatory blister fluid following oral administration.
Namour F; Sultan E; Pascual MH; Lenfant B
J Antimicrob Chemother; 2002 Jun; 49(6):1035-8. PubMed ID: 12039900
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.
Odenholt I; Löwdin E; Cars O
Antimicrob Agents Chemother; 2001 Jan; 45(1):23-9. PubMed ID: 11120939
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses.
Namour F; Wessels DH; Pascual MH; Reynolds D; Sultan E; Lenfant B
Antimicrob Agents Chemother; 2001 Jan; 45(1):170-5. PubMed ID: 11120961
[TBL] [Abstract][Full Text] [Related]
7. [Activity of telithromycin and other oral antibiotics against respiratory tract pathogens with acquired mechanisms of resistance].
Gómez-Garcés JL; Alós JI; Hernáiz C; Gómez C
Enferm Infecc Microbiol Clin; 2004; 22(6):323-7. PubMed ID: 15228898
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study.
Quinn J; Ruoff GE; Ziter PS
Clin Ther; 2003 Feb; 25(2):422-43. PubMed ID: 12749505
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
Stratton CW; Brown SD
Clin Ther; 2004 Apr; 26(4):522-30. PubMed ID: 15189749
[TBL] [Abstract][Full Text] [Related]
10. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
Mazzariol A; Koncan R; Vitali LA; Cornaglia G
J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
[TBL] [Abstract][Full Text] [Related]
11. Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.
Nagai K; Davies TA; Ednie LM; Bryskier A; Palavecino E; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2001 Nov; 45(11):3242-5. PubMed ID: 11600391
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
Zhanel GG; Johanson C; Hisanaga T; Mendoza C; Laing N; Noreddin A; Wierzbowski A; Hoban DJ
J Antimicrob Chemother; 2004 Dec; 54(6):1072-7. PubMed ID: 15531596
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial.
Shi J; Montay G; Bhargava VO
Clin Pharmacokinet; 2005; 44(9):915-34. PubMed ID: 16122280
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora.
Edlund C; Alván G; Barkholt L; Vacheron F; Nord CE
J Antimicrob Chemother; 2000 Nov; 46(5):741-9. PubMed ID: 11062193
[TBL] [Abstract][Full Text] [Related]
15. Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.
Zeitlinger M; Wagner CC; Heinisch B
Clin Pharmacokinet; 2009; 48(1):23-38. PubMed ID: 19071882
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis/tonsillitis.
Norrby SR; Rabie WJ; Bacart P; Mueller O; Leroy B; Rangaraju M; Butticaz-Iroudayassamy E
Scand J Infect Dis; 2001; 33(12):883-90. PubMed ID: 11868759
[TBL] [Abstract][Full Text] [Related]
17. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections.
Yassin HM; Dever LL
Expert Opin Investig Drugs; 2001 Feb; 10(2):353-67. PubMed ID: 11178347
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species.
Jalava J; Kataja J; Seppälä H; Huovinen P
Antimicrob Agents Chemother; 2001 Mar; 45(3):789-93. PubMed ID: 11181362
[TBL] [Abstract][Full Text] [Related]
19. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
Lorenz J
Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of ketolides telithromycin and HMR 3004 against italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility.
Giovanetti E; Montanari MP; Marchetti F; Varaldo PE
J Antimicrob Chemother; 2000 Dec; 46(6):905-8. PubMed ID: 11102408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
